Abstract
Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases. In many breast cancer lines, E-cadherin transcription is extinguished, but the role and significance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved. To gain further insights into mechanisms underlying E-cadherin inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad−). All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids. Elements in the proximal 108 bp of the E-cadherin promoter, when present in reporter gene constructs, were sufficient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in E-cad− parental lines and hybrids. E-cadherin expression could not be restored in E-cad− lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor. Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Behrens J, Lowrick O, Klein-Hitpass L and Birchmeier W. . 1991 Proc. Natl. Acad. Sci. USA 88: 11495–11499.
Behrens J, Mareel MM, van Roy FM and Birchmeier W. . 1989 J. Cell Biol. 108: 2435–2447.
Berx G, Cleton-Jansen A-M, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C and van Roy F. . 1995a EMBO J. 14: 6107–6115.
Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJG, van Bokhoven A and van Roy F. . 1995b Genomics 26: 281–289.
Birchmeier W and Behrens J. . 1994 Biochim. Biophys. Acta 1198: 11–26.
Bussemakers MJG, Giroldi LA, van Bokhoven A and Schalken JA. . 1994 Biochem. Biophys. Res. Commun. 203: 1284–1290.
Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin S. . 1999 Nature Genet. 21: 103–107.
Freshney RI. . 1994 Culture of Animal Cells: a Manual of Basic Technique. Wiley-Liss, Inc.: New York, NY. pp. 389–391.
Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M and Cano A. . 1993 Am. J. Pathol. 142: 987–993.
Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BAJ and Caldas C. . 1998 Cancer Res. 58: 4086–4089.
Giroldi LA, Bringuier P-P, de Weijert M, Jansen C, van Bokhoven A and Schalken JA. . 1997 Biochem. Biophys. Res. Commun. 241: 453–458.
Gossen M and Bujard H. . 1992 Proc. Natl. Acad. Sci. USA 89: 5547–5551.
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB. . 1995 Cancer Res. 55: 5195–5199.
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A and Reeve AE. . 1998 Nature 392: 402–405.
Hennig G, Behrens J, Truss M, Frisch S, Reichmann E and Birchmeier W. . 1995 Oncogene 11: 475–484.
Hennig G, Lowrick O, Birchmeier W and Behrens J. . 1996 J. Biol. Chem. 271: 595–602.
Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D and Gray J. . 1998 Cancer Res. 58: 1972–1977.
Ji X, Woodard AS, Rimm DL and Fearon ER. . 1997 Cell Growth Differ. 8: 773–778.
Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker K-F, Mueller J, Siewert JR and Hofler H. . 1999 Am. J. Path. 155: 337–342.
Mader S and White JH. . 1993 Proc. Natl. Acad. Sci. U.S.A. 90: 5603–5607.
Mansouri A, Spurr N, Goodfellow PN and Kemler R. . 1988 Differentiation 38: 67–71.
Natt E, Magenis RE, Zimmer J, Mansouri A and Scherer G. . 1989 Cytogenet. Cell. Genet. 50: 145–148.
Pierceall WE, Woodard AS, Morrow JS, Rimm D and Fearon ER. . 1995 Oncogene 11: 1319–1326.
Poola I, Williams DM, Koduri S, Ramprakash J, Taylor RE and Hankins WD. . 1998 Anal. Biochem. 258: 209–215.
Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA and Isola JJ. . 1996 Anat. Pathol. 105: 394–402.
Takeichi M. . 1991 Science 251: 1451–1455.
Vleminckx K, Vakaet L, Mareel M, Fiers W and van Roy F. . 1991 Cell 66: 107–119.
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S. . 1995 Proc. Natl. Acad. Sci. USA 92: 7416–7419.
Acknowledgements
This work was supported by NIH grants RO1CA70097 and 5 T32 CA09676-08. JH White generously provided the pGRE5/EBV vector.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hajra, K., Ji, X. & Fearon, E. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18, 7274–7279 (1999). https://doi.org/10.1038/sj.onc.1203336
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203336
Keywords
This article is cited by
-
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
Signal Transduction and Targeted Therapy (2023)
-
Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy
Medical Oncology (2022)
-
A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells
Breast Cancer Research and Treatment (2017)
-
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers
Breast Cancer Research (2014)
-
The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis
Oncogene (2013)